WallStreetZenWallStreetZen

NASDAQ: THAR
Tharimmune Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$1.15+0.02 (+1.77%)
Updated Apr 21, 2025
THAR Price
$1.15
Fair Value Price
$2.75
Market Cap
$2.43M
52 Week Low
$0.95
52 Week High
$6.45
P/E
-0.12x
P/B
1.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.85
Operating Cash Flow
-$11M
Beta
0.72
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

THAR Overview

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapies for treatment resistant cancers. Its approach targets ferroptosis, an anti-cancer mechanism resulting in iron-mediated cancer cell death. Hillstream BioPharma was incorporated in 2017 and is based in Bridgewater, NJ.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine THAR's potential to beat the market

View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
THAR
RankedUnranked of 462

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Protalix Biotherapeutics (PLX)
$2.55A
Aurinia Pharmaceuticals (AUPH)
$7.66A
Catalyst Pharmaceuticals (CPRX)
$22.02A
View Top Biotech Stocks

Be the first to know about important THAR news, forecast changes, insider trades & much more!

THAR News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how THAR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

THAR ($1.15) is undervalued by 58.12% relative to our estimate of its Fair Value price of $2.75 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
THAR ($1.15) is significantly undervalued by 58.12% relative to our estimate of its Fair Value price of $2.75 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
THAR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more THAR due diligence checks available for Premium users.

Valuation

THAR fair value

Fair Value of THAR stock based on Discounted Cash Flow (DCF)

Price
$1.15
Fair Value
$2.75
Undervalued by
58.12%
THAR ($1.15) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
THAR ($1.15) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
THAR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

THAR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.12x
Industry
-184.27x
Market
27.14x

THAR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.85x
Industry
4.04x
THAR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

THAR's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.8M
Profit Margin
0%
THAR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$3.7M
Liabilities
$2.4M
Debt to equity
1.85
THAR's short-term assets ($3.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
THAR's short-term assets ($3.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
THAR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
THAR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$3.0M
Investing
$0.0
Financing
$1.8M
THAR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

THAR vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
THAR–$2.43M+1.77%-0.12x1.85x
ENSC–$2.33M-5.68%-0.14x0.63x
GLMD–$2.32M+1.45%-0.17x0.14x
ONVOC$2.55M+1.74%-0.17x6.99x
ADTXD$2.59M-10.80%-0.00x5.21x
View Top Biotech Stocks

Tharimmune Stock FAQ

What is Tharimmune's quote symbol?

(NASDAQ: THAR) Tharimmune trades on the NASDAQ under the ticker symbol THAR. Tharimmune stock quotes can also be displayed as NASDAQ: THAR.

If you're new to stock investing, here's how to buy Tharimmune stock.

What is the 52 week high and low for Tharimmune (NASDAQ: THAR)?

(NASDAQ: THAR) Tharimmune's 52-week high was $6.45, and its 52-week low was $0.95. It is currently -82.17% from its 52-week high and 20.8% from its 52-week low.

How much is Tharimmune stock worth today?

(NASDAQ: THAR) Tharimmune currently has 2,108,753 outstanding shares. With Tharimmune stock trading at $1.15 per share, the total value of Tharimmune stock (market capitalization) is $2.43M.

Tharimmune stock was originally listed at a price of $1,305.00 in Jan 12, 2022. If you had invested in Tharimmune stock at $1,305.00, your return over the last 3 years would have been -99.91%, for an annualized return of -90.41% (not including any dividends or dividend reinvestments).

How much is Tharimmune's stock price per share?

(NASDAQ: THAR) Tharimmune stock price per share is $1.15 today (as of Apr 21, 2025).

What is Tharimmune's Market Cap?

(NASDAQ: THAR) Tharimmune's market cap is $2.43M, as of Apr 22, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tharimmune's market cap is calculated by multiplying THAR's current stock price of $1.15 by THAR's total outstanding shares of 2,108,753.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.